Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
166 hedge funds and large institutions have $1.18B invested in Esperion Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 52 increasing their positions, 60 reducing their positions, and 27 closing their positions.
50% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $16.5M
2.05% less ownership
Funds ownership: 115.76% → 113.7% (-2.1%)
9% less funds holding
Funds holding: 182 → 166 (-16)
13% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 60
28% less capital invested
Capital invested by funds: $1.64B → $1.18B (-$464M)
41% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$46.2M |
| 2 |
AG
Artal Group
Luxembourg
|
+$9.9M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$8.01M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.98M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$6.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$28.7M |
| 2 |
Goldman Sachs
New York
|
-$10.6M |
| 3 |
Millennium Management
New York
|
-$10.4M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$7.97M |
| 5 |
Barclays
London,
United Kingdom
|
-$6.87M |
ESPR Hedge Fund Activity: Q3 2020 in Review
166 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2020, worth a combined $1.18B — down 28% from $1.64B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ESPR and 16 opened new positions — a net loss of 11 holders — while 60 trimmed existing stakes and 52 added.
The largest buyer was Wasatch Advisors, adding an estimated $46.2M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $28.7M sold.
- 166 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2020, down from 182 in Q2 2020.
- Funds reported $1.18B of Esperion Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
- 16 funds opened new Esperion Therapeutics positions in Q3 2020 and 27 closed out, a net change of -11 holders.
- The largest Esperion Therapeutics buyer in Q3 2020 was Wasatch Advisors, an estimated $46.2M added.
- The largest Esperion Therapeutics seller in Q3 2020 was Avidity Partners Management, an estimated $28.7M sold.
Based on aggregated 13F filings for Q3 2020.